Immunosuppression Clinical Trial
— PIP-02Official title:
A Prospective Comparison of the Magnitude and Character of the Immune Response to Influenza Vaccine in Immunosuppressed Renal Transplant Patients and Healthy Age-matched Volunteers
Verified date | November 2013 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Influenza (Flu) vaccine is recommended for kidney transplant patients who are at least 6
months post-transplant. The influenza vaccine stimulates the immune system to builds
protective antibodies against the flu virus.
Previous research has shown that adult kidney transplant patients are not able to form as
much of these protective antibodies as compared to healthy volunteers. Research has also
suggested that different immunosuppressive medicines may have different effects on antibody
formation. In this study, we hope to evaluate these differences in more detail.
In recent years, increasingly effective, but also increasingly complex, immunosuppressive
regimens have been developed, however, there has been little detailed systematic study of
the immune changes that occur in response to vaccination with these newer immunosuppressive
regimens.Current policies on vaccination of transplant recipients are generic and continue
to be based on old concepts rather than on any new understanding of the effects of these
newer therapies on the immune system.
We hope to improve our understanding of the effects of the immunosuppressive regimens in use
today (calcineurin-inhibitor, or CNI, and sirolimus-based regimens) on immune response to
flu vaccine. Such knowledge will be critical to helping clinicians develop strategies for
getting desirable immune responses while not causing rejection.
Status | Completed |
Enrollment | 97 |
Est. completion date | October 2011 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 59 Years |
Eligibility |
Inclusion Criteria: 1. Male or female patients between 18 and 59 years of age 2. Greater than six months post deceased or living donor renal transplant 3. Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study. 4. Patients with no known contraindications to flu vaccine (e.g. egg allergy, prior serious adverse reaction to flu vaccine, current febrile illness, marked leukopenia (WBC < 2500 cells/ml) 5. Women of childbearing potential must have a negative serum pregnancy test within 7 days of study enrollment and must not be breast-feeding. Exclusion Criteria: 1. Patients with evidence of an active systemic infection |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the effect of immunosuppressive regimens on the magnitude and character of the adaptive immune response to flu vaccine | 7, 14, 28 and 90 days post vaccination | No | |
Primary | To determine the effects of chronic immunosuppressive therapies on innate immunity during response to flu vaccine | 7, 14, 28 and 90 days post vaccination | No | |
Primary | To define the transcriptional and protein signatures of the response to flu vaccination in patients on conventional immunosuppressive regimens compared to healthy volunteers | 7, 14, 28 and 90 days post vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT02833805 -
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
|
Phase 2 | |
Completed |
NCT01252537 -
Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
|
N/A | |
Completed |
NCT01678937 -
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
|
N/A | |
Completed |
NCT00621699 -
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00788021 -
Protective Immunity Project 01
|
N/A | |
Active, not recruiting |
NCT00166842 -
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
|
Phase 4 | |
Recruiting |
NCT05616130 -
Pathological Myeloid Activation After Sepsis and Trauma
|
||
Completed |
NCT03117192 -
Zinc Supplementation on Cellular Immunity in Thalassemia Major
|
Phase 4 | |
Recruiting |
NCT01568697 -
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
|
||
Not yet recruiting |
NCT06024226 -
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
|
||
Not yet recruiting |
NCT04961229 -
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
|
Phase 4 | |
Completed |
NCT03139565 -
High Dose vs. Standard Influenza Vaccine in Adult SOT
|
Phase 3 | |
Completed |
NCT02547753 -
Dental Extractions Among Renal Transplant Recipients
|
||
Completed |
NCT01702207 -
Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk
|
Phase 4 | |
Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
Completed |
NCT00419575 -
Renal Transplantation With Immune Monitoring
|
N/A | |
Completed |
NCT00783380 -
Influenza Vaccination in Immunocompromized Patients
|
Phase 4 | |
Completed |
NCT04835948 -
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
|
||
Recruiting |
NCT05043870 -
Combined Immunosuppression for Pediatric Crohn's Disease
|
Phase 4 |